Sophia Zoungas

Tirzepatide is associated with ~28% lower MACE-3 risk versus imputed placebo in T2D and ASCVD.

Opioid Use Is Associated With Lower Health‐Related Quality of Life Among Community‐Dwelling Older Australians: A Cross‐Sectional Study From STAREE

BACKGROUND: Prescribed opioid use among older adults may have a reciprocal negative association with health-related quality of life (HrQoL), yet evidence on this relationship remains limited. This study evaluated the association between prescription opioid use and HrQoL in community-dwelling older adults. METHODS: We conducted a secondary cross-sectional analysis of baseline STAtins in Reducing Events in Elderly (STAREE) trial data, assessing the association between self-reported prescribed opioid use and HrQoL, via the 36-item Short Form Survey. Multivariable linear regression models assessed the association, with progressive adjustment for sociodemographic (Models 1 and 2), clinical (Model 3), and psychosocial factors (Model 4). Propensity score matching (PSM) was conducted to assess the robustness of the association. FINDINGS: The cohort included 479 opioid users and 9492 non-opioid users. users. In unadjusted analyses, opioid users had substantially lower mean HrQoL scores than non-users (β = -14.30; 95% CI: -15.59, -13.02). Adjustment for confounders attenuated the association, but it remained statistically significant in the fully adjusted model (β = -7.58; 95% CI: -8.80, -6.35). Lower scores among opioid users were observed across all HrQoL domains (Physical Functioning, Social Functioning, Role Limitations, Vitality, Bodily Pain, General Health and Mental Health), with the largest differences in physical functioning (approximately 20-25 points lower). CONCLUSION: Opioid use is associated with significantly poorer HrQoL in community-dwelling older adults, highlighting the importance of routinely assessing quality of life, functional status, and psychosocial factors among persons who use opioids. TRIAL REGISTRATION: This study was approved by Monash Human Research Ethics Committee (ID: 21528).

Beyond Health Outcomes: Broader Societal Impacts in Economic Evaluations of Type 1 Diabetes Technologies

Population genomic screening for familial hypercholesterolaemia is cost-effective if test costs remain under AU$250.

Statin therapy shows no association with incident dementia or cognitive decline in older adults.

Among adults with type 2 diabetes, there was substantial heterogeneity and limited overlap between anatomical, genetic, and clinical cardiovascular risk measures, with only 8.7% classified as high risk across all three domains.

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study

Ongoing VOLTAIRE trial tests if adding CTCA or PRS to counseling improves type 2 diabetes outcomes.

Beta-blockers post-MI fail to reduce mortality but cut recurrent MI by ~20%.

Aspirin reduces major CV events ~66% vs placebo in hypertensive patients with eGFR <45.

Geographic Variation in Loneliness and Social Isolation in Australia: Socio-Demographic and Healthcare Utilisation Determinants

Higher cumulative SBP load is linked to ~14% more major cardiovascular events in T2D.

Tirzepatide cuts MACE-3 by ~28% vs imputed placebo in indirect comparison.

Beta-blocker therapy after PCI was associated with higher all-cause mortality in patients with preserved (OR 1.46) and mildly reduced LVEF (OR 1.48), with no benefit in those with lower LVEF.

NichollsNew England Journal of Medicine

Tirzepatide demonstrates noninferiority to dulaglutide for major adverse cardiovascular events in T2D and ASCVD.

Automated Insulin Delivery Is Associated with Reduced Hospital Admissions and Costs for Acute Diabetes Complications in Children with Type 1 Diabetes

This study evaluated the association between insulin regimen, hospitalization for acute diabetes complications, and related health care costs in children with type 1 diabetes (T1D). Hospital admissions for diabetic ketoacidosis or hypoglycemia between January 5, 2022, and April 30, 2024, were analyzed in Western Australian children with T1D. Admissions due to newly diagnosed T1D were excluded. Incidence rate ratios were calculated using generalized estimating equations, adjusted for age, diabetes duration, and socioeconomic status. Costs were valued using the 2023–2024 Australian hospital data. Among 1440 children with T1D (2674 patient-years of follow-up), admission rates per 100 patient-years were 1.98 for automated insulin delivery (AID), 3.34 for non-AID pump, and 5.86 for insulin injections, with respective costs of AUD 20,132, 34,008, and 59,574. Compared with AID, adjusted hospitalization rate ratios were 2.74 (95% confidence interval [CI]: 1.39–5.42; P = 0.0036) for multiple daily injections (MDI) and 1.62 (95% CI: 0.84–3.14; P = 0.150) for non-AID pump. AID use is associated with lower admission rates and ∼$40,000 savings per 100 patient-years compared with MDI.

Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked Dataset